Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
STAT+
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

7 challenges that could make or break Biogen’s 2022

  • Damian Garde
  • Adam Feuerstein
  • Rachel Cohrs

By Damian Garde , Adam Feuerstein and Rachel Cohrs Dec. 23, 2021

Reprints
Cambridge: Biogen
Ruby Wallau for STAT

Can Biogen pull itself back from the brink?

The company is ending 2021 with dismal sales of its treatment for Alzheimer’s disease and its stock depressed. Management is slashing the drug’s price and cutting expenses.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Rachel Cohrs

Rachel Cohrs

Washington Correspondent

Rachel Cohrs reports on the intersection of politics and health policy.

Tags

Create a display name to comment

This name will appear with your comment

Experts weigh in on potential health hazards posed by…
Experts weigh in on potential health hazards posed by chemicals in Ohio train derailment
‘Microdosing’ is touted by ’shroomers and Reddit users. Science…
‘Microdosing’ is touted by ’shroomers and Reddit users. Science is starting to test their claims —…
Flawed herpes testing leads to many false positives —…
Flawed herpes testing leads to many false positives — and needless suffering
Takeda autoimmune therapy shows effectiveness in key trial
Takeda autoimmune therapy shows effectiveness in key trial
Moderna CEO made $398 million in 2022, but still…
Moderna CEO made $398 million in 2022, but still pledges to give most to charity
Up and down the ladder: The latest comings and…
Up and down the ladder: The latest comings and goings

Recommended Stories